ACC 100

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of ACC 100

What is ACC 100?

ACC 100 is a pharmacological agent belonging to the class of medications known as mucolytics. It is primarily utilized to assist in the management of respiratory conditions characterized by the production of thick, tenacious mucus. By acting directly on the chemical structure of the mucus, ACC 100 helps to alter its physical properties, making it easier for the body to clear from the airways.

Mechanism of Action

The active component in ACC 100 works by breaking the disulfide bonds that hold mucoprotein molecular chains together. When these bonds are disrupted, the viscosity of the bronchial secretions is significantly reduced. This thinning effect facilitates the natural removal process of the mucus through coughing or other ciliary actions of the respiratory tract.

Therapeutic Role

ACC 100 is often integrated into the management plan for various acute and chronic respiratory disorders. These may include:

  • Bronchitis: Inflammation of the bronchial tubes that results in increased mucus production.
  • Chronic Obstructive Pulmonary Disease (COPD): Long-term lung conditions where airway clearance is often compromised.
  • Cystic Fibrosis: A genetic condition where exceptionally thick mucus can obstruct respiratory pathways.

In addition to its mucolytic properties, the compound serves as a precursor to glutathione, a significant antioxidant found in the body. This role supports the cellular defense mechanisms against oxidative stress, which is frequently associated with inflammatory processes in the lungs.

What side effects are possible with ACC 100?

Possible side effects and safety information

The safety profile of Acetylcysteine (ACC 100) is structured by government regulatory agencies based on the frequency and the System-Organ Class (SOC) affected. The most common adverse reactions reported in official documents relate to the Gastrointestinal and Immune Systems.

Officially documented adverse reactions are categorized by their observed frequency, primarily using the regulatory tiers established in sources like the Summary of Product Characteristics (SmPC):

Classification Example Adverse Reactions (SOC)
Uncommon Hypersensitivity reactions (e.g., rash, pruritus), Headache, Tinnitus, Pyrexia
Rare Dyspepsia, Stomatitis
Very Rare Anaphylactic/anaphylactoid reaction, Hemorrhage

Serious adverse reactions documented in regulatory sources include rare events such as anaphylactic shock and severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), the frequency of which is classified as Not Known. These serious events involve the Vascular, Immune System, and Skin/Subcutaneous Tissue SOCs.

Population-Specific Safety Notes

The official labeling notes specific safety considerations for certain patient populations. Caution is documented for individuals with a history of bronchial asthma due to the potential for bronchospasm. Similarly, patients with a history of peptic ulcers are noted due to the documented risk of gastrointestinal hemorrhage. The medicine is formally contraindicated if a patient has a known hypersensitivity to the active substance or any of its excipients. Hypersensitivity reactions may manifest particularly at the onset of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents detail specific manifestations and mandatory emergency actions in the event of an overdose with Acetylcysteine. Overdose presentations are documented to include a range of systemic and cutaneous signs, such as hypotension, tachycardia, facial flushing, rash, urticaria, and bronchospasm.

More severe and life-threatening outcomes, as described in regulatory-aligned literature, include fatal anaphylaxis, seizures, and the potential for acute organ system compromise, such as cerebral edema and acute renal failure.

Immediate medical attention is required upon observation of any serious manifestations, including severe hypotension, wheezing, shortness of breath, or signs of a systemic reaction. Clinical response requires the immediate discontinuation of drug administration and the initiation of appropriate supportive treatment. For oral overdose management, the official labels describe that the stomach should be emptied promptly by lavage or induced emesis.

Management is strictly symptomatic and supportive, as no specific antidote for Acetylcysteine itself is known. Continuous hospital monitoring of hepatic function, renal function, and electrolytes is a recommended procedural step. Furthermore, population-specific regulatory notes require that the total fluid volume administered be reduced for patients weighing less than 40 kg to prevent fluid overload.

Therapeutic Uses of ACC 100

What ACC 100 Treats: Main Uses and Benefits

Easing the Burden of Thick Respiratory Mucus

The medication is used to address symptom clusters that may become intense or disruptive, specifically those related to viscid (thick) and tenacious (sticky) phlegm in the respiratory tract. Its use is relevant for managing symptoms that interfere with daily comfort in conditions presenting with acute episodes, such as acute bronchitis, and in chronic airway diseases like COPD and cystic fibrosis. Its use is considered relevant across domains where additional symptomatic support is needed for conditions presenting with abnormal mucous secretions in bronchopulmonary diseases. The primary benefit is providing supportive relief that may help manage the symptoms related to physical discomfort caused by difficulty in clearing phlegm, assisting with maintaining functional stability and contributing to improved day-to-day comfort during symptomatic periods. The agent is utilized to assist with abnormal mucous secretions in bronchopulmonary diseases.

Acute Antidote and Organ Support in Toxicology

A separate, specialized therapeutic domain is applied in clinical settings that involve acute toxic ingestion. It is commonly used as an agent applied in addressing acute toxic ingestion following an overdose of acetaminophen (paracetamol), relevant in contexts involving heightened systemic burden. In this emergency scenario, it provides support that helps maintain a sense of stability when symptoms are more noticeable, offering supportive relief that may assist with functional stability during this critical phase.


“ACC 100 provides support that helps ease the overall symptom burden associated with chest congestion and persistent, thick phlegm.”

Quick Fact: Applied in contexts where short-term symptomatic assistance is needed for viscid mucous secretions.

Regulatory References

  1. DailyMed official drug label for Acetylcysteine

Eligibility and Restrictions for Use

Official Regulatory Eligibility for ACC 100

The eligibility for ACC 100 (Acetylcysteine) is strictly defined by regulatory authorities based on population groups and pre-existing conditions.


Populations for whom use is contraindicated (Must Not Use):

  • Patients with documented hypersensitivity or allergy to acetylcysteine or any component of the formulation.
  • Children under 2 years of age for the mucolytic indication, due to the risk of airway obstruction.
  • Patients with active peptic ulceration.

Age-Related Eligibility Rules:

  • The medicine is approved for adults and adolescents (typically starting at 14 years).
  • Lower-strength formulations are permitted for children aged 2 years and older.

Eligibility-Related Restrictions:

  • Use requires special caution for patients with asthma or a history of bronchospasm, necessitating close medical supervision.
  • Caution is also required for patients with a history of stomach ulcers or those at risk of gastric hemorrhage.
  • Elderly or frail patients should be monitored due to the potential for a reduced cough reflex, which may affect clearance of secretions.

Pregnancy and Lactation Status:

  • Use is generally not recommended during pregnancy and lactation due to insufficient human safety data, and should only occur following a strict benefit-risk assessment by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation details specific interaction patterns for Acetylcysteine (ACC 100) that impose administration restrictions and require monitoring.


Pharmacodynamic and Chemical Interactions

Co-administration with antitussive agents (cough suppressants) is advised against, as the reduction of the cough reflex can prevent the clearance of the increased bronchial secretions caused by the mucolytic action of ACC 100.

When combined with Nitroglycerin, the potential for additive effects on blood pressure exists; this combination may potentiate the vasodilatory and hypotensive effect of Nitroglycerin. Monitoring for low blood pressure is specified.

Due to the risk of in vitro inactivation with agents like oral antibiotics (e.g., Cephalosporins), a mandatory two-hour separation is required between the administration of oral antibiotics and ACC 100. Furthermore, the ACC 100 oral solution must not be mixed with other medicinal products in the same preparation.

Other Documented Constraints

Type of Constraint Interacting Substance/Condition Regulatory Outcome/Restriction
Excipient Constraint Aspartame (in effervescent forms) Caution for individuals with Phenylketonuria (PKU) due to phenylalanine content.
Laboratory Test Interference Salicylates; Ketones Officially documented interference with specific colorimetric assay methods for these substances.
Absorption Constraint Activated Charcoal May reduce the effectiveness of Acetylcysteine, particularly during its use as an acute antidote.

These constraints define the necessary administration requirements and limitations that must be adhered to when using ACC 100 alongside other medicines or during clinical testing procedures.

Mechanism of Action

ACC 100, which contains acetylcysteine, functions as a reductant and free radical scavenger, primarily targeting the disulfide bonds within mucoproteins and impacting intracellular glutathione levels. Within the respiratory tract secretions, the sulfhydryl group of acetylcysteine interacts with and cleaves the disulfide linkages that cross-link the mucin oligomers. This process results in the depolymerization of high molecular weight mucoproteins, leading to a reduction in the viscosity and elasticity of the secretions.

Intracellularly, acetylcysteine serves as a precursor for the amino acid L-cysteine by undergoing deacetylation. L-cysteine is a substrate required for the synthesis of glutathione ( gamma -L-glutamyl-L-cysteinylglycine), a key endogenous antioxidant. By increasing the available pool of L-cysteine, the drug stimulates glutathione synthesis, thereby modulating the intracellular redox state. This increase in glutathione can directly conjugate electrophilic intermediate compounds, influencing cellular signaling pathways dependent on redox balance.

Dosage and Administration Information

How to Use ACC 100: General Administration Guidelines

Acetylcysteine (ACC 100) administration follows distinct, standardized protocols depending on the intended use, covering both its common mucolytic application and its specialized antidote treatment for acute acetaminophen toxicity.


Administration Scope

Feature General Administration Principles
Route of Administration The medicine is approved for Oral (effervescent tablets, granules, or solution), Intravenous (IV) infusion, and Inhalation via nebulization or direct instillation.
Dosing Schedule Mucolytic Use: Standard regimens include 600 mg once daily or 200 mg three times daily (total 600 mg/day). Antidote Use: Requires a strict, weight-based regimen, such as a total of 300 mg/kg administered via a three-infusion IV protocol over 21 hours.
Preparation Requirements Oral dosage forms like effervescent tablets and granules must be dissolved completely in water before being taken. Solutions for injection must be diluted in appropriate intravenous fluids before infusion is started.
Course Duration Use for acute conditions is typically short-term, lasting 5 to 10 days. For chronic respiratory conditions, use may be extended for up to six months.
Special Administration Conditions Concomitant Use: Oral antibiotics should be taken at least two hours before or after oral acetylcysteine administration. Antidote Timing: Treatment initiation should occur within eight hours of acute ingestion for maximal protective effect.
Age-Group Rules Total administered IV fluid volume for antidote use must be adjusted for patients weighing less than 40 kg. Pediatric doses for mucolytic use, such as 200 mg daily for infants, are specified for certain formulations.

Connection to the Overall Use Protocol

The standardized protocols establish a rigorous structure for administration, clearly differentiating between the low-dose, daily schedules for mucolytic applications and the high-dose, time-critical, multi-step infusion protocols for use as an antidote. This structure defines the precise frequency, preparation, and duration rules that apply according to the specific context of the medicine's use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for ACC 100

Evidence for use in Chronic Fatigue Syndrome (CFS)

Research has explored the use of ACC 100 in individuals with Chronic Fatigue Syndrome (CFS), a condition marked by functional limitations. Researchers utilized short-term and intermediate-term Randomized Controlled Trials (RCTs), alongside some open-label studies, primarily focusing on adult populations. The studies examined changes in patient-reported outcomes, such as fatigue and function, and monitored how symptoms evolved in the observed populations. Research documents measurements recorded during the study period, consistent with how patients reported their experience.

It is important to understand that the evidence is limited for this indication. The follow-up durations were limited, meaning long-term effects are not fully established. Also, the sample sizes were modest in many trials, and data for certain groups remain insufficient.


Evidence for use in Fibromyalgia (FM)

Research has evaluated ACC 100 in individuals with Fibromyalgia, a condition characterized by fluctuating manifestations and outcomes related to physical discomfort. Research primarily involved short-term RCTs that focused on measuring patient-reported outcomes. The research explored changes in core measurements, such as pain and sleep quality, over time, by monitoring scores related to pain intensity, sleep quality, and daily functioning. The findings provide insight into short-term changes in these patient-reported outcomes.

While research exists, the certainty remains low regarding the long-term impact. There is limited information for long-term outcomes beyond approximately six months. Furthermore, comparative evidence is lacking against all other available therapies. Because this research involves conditions where symptoms may vary in intensity, the evidence quality varies across studies.


Long-term studies and follow-up

Research exploring short-term symptom changes was observed in most of the available studies. These studies offer insights over defined time intervals that are generally short-term to intermediate-term. Currently, there is a lack of comprehensive evidence from studies with extended follow-up, meaning long-term effects are not fully established and the durability of the observed patterns is still uncertain.


What is still uncertain about ACC 100

The current body of research contributes to the broader evidence landscape but has several important limitations. Sample sizes were modest and follow-up durations were limited. Findings were mixed across different studies, and the reliance on patient-reported outcomes means that individual patient experiences may differ from the group averages reported in the studies. The research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about ACC 100 (FAQ)


Q: Is ACC 100 an antibiotic, a cough suppressant, or something else?

A: ACC 100 is classified primarily as a mucolytic agent. This means its main purpose is to break down and thin thick mucus. According to official product information, it is not an antibiotic. Furthermore, regulatory guidelines advise against using it alongside strong cough suppressants, as its action is to help you clear the thinned mucus.


Q: Does taking ACC 100 with food or an empty stomach make a difference?

A: Some formulations of acetylcysteine are instructed to be taken dissolved in water after meals. These administration requirements are set to optimize effectiveness and tolerability. Patients are directed to consult the product's official patient information leaflet, as instructions can vary based on the specific formulation.


Q: What are the components or excipients in the ACC 100 formulation besides the active ingredient?

A: The ACC 100 product contains the active ingredient, acetylcysteine, along with various excipients (inactive ingredients). Common excipients found in effervescent tablets may include lactose, sucrose, sodium compounds, and flavoring agents. The complete list of these components is available within the official regulatory labeling for the specific product presentation.


Q: Is ACC 100 available in different forms (e.g., effervescent tablet, powder, syrup)?

A: The active ingredient, acetylcysteine, is manufactured in multiple forms to suit different needs. These forms commonly include effervescent tablets, granules for oral solution, and sterile injectable solutions for hospital use. The availability of other forms, such as a syrup, depends on the specific brand and country’s approval.


Q: Is ACC 100 safe for women who are breastfeeding?

A: Official regulatory documents generally state that use during lactation is not recommended due to a lack of sufficient human safety data. While some labels note that effects on the infant are not expected at therapeutic doses, caution is advised. Use, if considered, must be preceded by a strict benefit-risk assessment conducted by a healthcare professional.


Q: What are the general recommendations for pregnant women regarding ACC 100?

A: The use of ACC 100 during pregnancy is generally not recommended because there is insufficient human data to confirm its safety. Use during this time is generally considered only when essential, and initiation must be preceded by a strict risk-benefit assessment performed by a healthcare professional.


Q: Does ACC 100 treat a dry cough or a wet, productive cough?

A: ACC 100 is indicated for conditions involving the overproduction of viscous mucus or thick phlegm. Its purpose is to thin the secretions and help the body clear them, meaning it is intended to address a wet or productive cough.


Q: Is ACC 100 only for lung congestion or does it help with sinus congestion too?

A: Official indications primarily approve ACC 100 for reducing the viscosity of bronchial secretions—the mucus found in the lower airways (lungs). While it acts on mucus generally, the regulatory scope focuses on facilitating the expectoration of phlegm from the respiratory tract.


Q: Why do people say ACC 100 tastes or smells like sulfur or rotten eggs?

A: The active substance, acetylcysteine, is a thiol compound, meaning it naturally contains sulfur. Therefore, the product can have a characteristic mild sulfurous odor. This scent is specific to the medicine and does not indicate that the preparation is damaged or ineffective.


Q: Is it normal to cough more after first starting ACC 100?

A: Yes, it can be normal. At the start of the treatment, the volume of bronchial secretions may temporarily increase. This is due to the drug’s liquefaction effect, which thins the mucus and prompts the body to cough more to clear the increased fluid.


Q: What is the difference between ACC 100 and other strengths of ACC (like ACC 200 or ACC 600)?

A: The number (e.g., 100, 200, 600) refers directly to the milligram strength of the active ingredient, acetylcysteine, in that particular dosage form. The different strengths are approved for different dosing schedules tailored for adults or children, depending on the therapeutic need.


Q: Are there studies supporting the use of ACC 100 for seasonal allergies?

A: The official regulatory indications for ACC 100 focus on respiratory conditions with thick mucus. The provided research evidence primarily documents studies exploring its use in conditions like Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM), not specifically seasonal allergies.


Q: Does ACC 100 have any recognized antioxidant properties?

A: Yes. Beyond its mucolytic action, acetylcysteine is utilized because it is a precursor for the amino acid L-cysteine. L-cysteine is essential for the synthesis of glutathione, which is a key endogenous antioxidant in the body.


Q: Is ACC 100 used for any other conditions besides respiratory mucus issues?

A: Yes, official documents support another critical use. Due to its action as a glutathione precursor, acetylcysteine is also used as a specialized antidote in the treatment of acute poisoning by acetaminophen (paracetamol) toxicity.


Q: Can ACC 100 be dissolved in drinks other than water?

A: The official preparation requirements state that oral dosage forms like effervescent tablets and granules must be dissolved completely in water before ingestion. Furthermore, the prepared oral solution must not be mixed with any other medicinal products in the same preparation.


Q: Is there a recommended maximum number of days for taking ACC 100?

A: The duration of treatment depends entirely on the condition being treated. For acute conditions, use is typically short-term, such as 8 to 10 days. However, for chronic respiratory conditions, use may be extended for longer periods, sometimes up to six months. The decision for long-term use should be based on clinical judgment.


Q: Is it better to take ACC 100 in the morning or evening?

A: Official labeling generally does not specify an optimal time of day for all patients. However, for specific patient groups, such as the elderly or weakened individuals with a reduced ability to cough, some formulations recommend taking the dose, preferably in the morning.


Q: Can taking ACC 100 make you drowsy or affect driving?

A: Official regulatory documentation for the oral forms of acetylcysteine typically does not note any effect on the ability to drive or use machinery. Therefore, effects such as drowsiness are considered unlikely with this medication.


Q: Does ACC 100 contain lactose, and is this a concern for people with intolerance?

A: Yes, some formulations, particularly the effervescent tablets, contain lactose. Official documents state that rare hereditary problems such as total lactase deficiency or galactose intolerance is a contraindication for taking this medicine.


Q: Are there any known issues with taking ACC 100 and being on a low-sodium diet?

A: Yes, patients on a controlled sodium diet, such as those with heart conditions, should be aware that some effervescent formulations contain sodium. The sodium content is a factor that must be considered in a patient's daily intake calculation.


Q: Can ACC 100 be taken with cough suppressants?

A: Official guidelines advise against the simultaneous use of ACC 100 with antitussive agents (cough suppressants). The primary reason is that preventing the cough reflex can prevent the body from clearing the thinned bronchial secretions caused by the mucolytic action.


Q: Is it normal for the color of the dissolved ACC 100 to change?

A: A change in the color of acetylcysteine solutions, such as turning a light purple, has been noted. For clinical preparations, this color change is generally not considered to indicate any significant loss of safety or efficacy.


Q: Can ACC 100 be used for long-term treatment of chronic lung conditions?

A: Yes, ACC 100 is indicated as an adjunct in the treatment of chronic respiratory conditions, such as chronic bronchitis. The use can be extended for long periods, typically up to six months or more. The decision for long-term use is based on clinical judgment.


Q: Do clinical trials suggest ACC 100 is effective for children's coughs?

A: The medicine is officially approved for specific doses in children aged two years and older for the mucolytic indication. This authorization is based on the therapeutic action of acetylcysteine in reducing mucus viscosity to help facilitate the clearance of phlegm.

How should ACC 100 be stored and disposed of?

How to Store and Dispose of ACC 100

Official regulatory labeling dictates specific conditions for storing and disposing of ACC 100 (Acetylcysteine effervescent tablets) to maintain product stability and ensure safety.


Storage Requirements

Category Requirement (Official Labeling)
Temperature Store below 30°C.
Protection Must be protected from moisture and light.
Container Rule Keep in the original package and keep the container tightly closed.
Prepared Solution The dissolved solution must be used immediately and not stored.

Disposal and Safety

Always keep ACC 100 out of the sight and reach of children.

Unused or expired product must not be thrown away into household waste or disposed of via wastewater. Patients must follow local regulations and consult a pharmacist for guidance on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of ACC 100 found in:

A-Z Index: